488 related articles for article (PubMed ID: 29580877)
1. Establishment of a novel microscale thermophoresis ligand-binding assay for characterization of SLC solute carriers using oligopeptide transporter PepT1 (SLC15 family) as a model system.
Clémençon B; Lüscher BP; Hediger MA
J Pharmacol Toxicol Methods; 2018; 92():67-76. PubMed ID: 29580877
[TBL] [Abstract][Full Text] [Related]
2. In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1.
Pak YA; Long AJ; Annes WF; Witcher JW; Knadler MP; Ayan-Oshodi MA; Mitchell MI; Leese P; Hillgren KM
Drug Metab Dispos; 2017 Feb; 45(2):137-144. PubMed ID: 27895114
[TBL] [Abstract][Full Text] [Related]
3. Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice.
Yang B; Smith DE
Drug Metab Dispos; 2013 Mar; 41(3):608-14. PubMed ID: 23264448
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of analogs of L-valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells.
Friedrichsen GM; Chen W; Begtrup M; Lee CP; Smith PL; Borchardt RT
Eur J Pharm Sci; 2002 Jul; 16(1-2):1-13. PubMed ID: 12113886
[TBL] [Abstract][Full Text] [Related]
5. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2.
Ganapathy ME; Huang W; Wang H; Ganapathy V; Leibach FH
Biochem Biophys Res Commun; 1998 May; 246(2):470-5. PubMed ID: 9610386
[TBL] [Abstract][Full Text] [Related]
6. The GFP thermal shift assay for screening ligand and lipid interactions to solute carrier transporters.
Chatzikyriakidou Y; Ahn DH; Nji E; Drew D
Nat Protoc; 2021 Dec; 16(12):5357-5376. PubMed ID: 34707255
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in understanding prodrug transport through the SLC15 family of proton-coupled transporters.
Minhas GS; Newstead S
Biochem Soc Trans; 2020 Apr; 48(2):337-346. PubMed ID: 32219385
[TBL] [Abstract][Full Text] [Related]
8. Targeting SLC transporters: small molecules as modulators and therapeutic opportunities.
Schlessinger A; Zatorski N; Hutchinson K; Colas C
Trends Biochem Sci; 2023 Sep; 48(9):801-814. PubMed ID: 37355450
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for prodrug recognition by the SLC15 family of proton-coupled peptide transporters.
Minhas GS; Newstead S
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):804-809. PubMed ID: 30602453
[TBL] [Abstract][Full Text] [Related]
10. Functionalized PLA-PEG nanoparticles targeting intestinal transporter PepT1 for oral delivery of acyclovir.
Gourdon B; Chemin C; Moreau A; Arnauld T; Baumy P; Cisternino S; Péan JM; Declèves X
Int J Pharm; 2017 Aug; 529(1-2):357-370. PubMed ID: 28705621
[TBL] [Abstract][Full Text] [Related]
11. Structure of Prototypic Peptide Transporter DtpA from E. coli in Complex with Valganciclovir Provides Insights into Drug Binding of Human PepT1.
Ural-Blimke Y; Flayhan A; Strauss J; Rantos V; Bartels K; Nielsen R; Pardon E; Steyaert J; Kosinski J; Quistgaard EM; Löw C
J Am Chem Soc; 2019 Feb; 141(6):2404-2412. PubMed ID: 30644743
[TBL] [Abstract][Full Text] [Related]
12. Thiodipeptides targeting the intestinal oligopeptide transporter as a general approach to improving oral drug delivery.
Foley DW; Pathak RB; Phillips TR; Wilson GL; Bailey PD; Pieri M; Senan A; Meredith D
Eur J Med Chem; 2018 Aug; 156():180-189. PubMed ID: 30006163
[TBL] [Abstract][Full Text] [Related]
13. Influence of PLA-PEG nanoparticles manufacturing process on intestinal transporter PepT1 targeting and oxytocin transport.
Gourdon B; Chemin C; Moreau A; Arnauld T; Delbos JM; Péan JM; Declèves X
Eur J Pharm Biopharm; 2018 Aug; 129():122-133. PubMed ID: 29803721
[TBL] [Abstract][Full Text] [Related]
14. High-Throughput Expression and Purification of Human Solute Carriers for Structural and Biochemical Studies.
Raturi S; Li H; Chang YN; Scacioc A; Bohstedt T; Fernandez-Cid A; Evans A; Abrusci P; Balakrishnan A; Pascoa TC; He D; Chi G; Kaur Singh N; Ye M; Li A; Shrestha L; Wang D; Williams EP; Burgess-Brown NA; Dürr KL; Puetter V; Ingles-Prieto A; Sauer DB
J Vis Exp; 2023 Sep; (199):. PubMed ID: 37843272
[TBL] [Abstract][Full Text] [Related]
15. Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR.
Prabhala BK; Aduri NG; Iqbal M; Rahman M; Gajhede M; Hansen PR; Mirza O
Res Microbiol; 2017 Jun; 168(5):443-449. PubMed ID: 28214542
[TBL] [Abstract][Full Text] [Related]
16. SLC Family Transporters.
Liu X
Adv Exp Med Biol; 2019; 1141():101-202. PubMed ID: 31571165
[TBL] [Abstract][Full Text] [Related]
17. Recognition and transport characteristics of nonpeptidic compounds by basolateral peptide transporter in Caco-2 cells.
Irie M; Terada T; Sawada K; Saito H; Inui K
J Pharmacol Exp Ther; 2001 Aug; 298(2):711-7. PubMed ID: 11454935
[TBL] [Abstract][Full Text] [Related]
18. Impact of peptide transporter 1 on the intestinal absorption and pharmacokinetics of valacyclovir after oral dose escalation in wild-type and PepT1 knockout mice.
Yang B; Hu Y; Smith DE
Drug Metab Dispos; 2013 Oct; 41(10):1867-74. PubMed ID: 23924683
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in ligands and chemical probes targeting solute carrier transporters.
Casiraghi A; Bensimon A; Superti-Furga G
Curr Opin Chem Biol; 2021 Jun; 62():53-63. PubMed ID: 33689964
[TBL] [Abstract][Full Text] [Related]
20. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir.
Balimane PV; Tamai I; Guo A; Nakanishi T; Kitada H; Leibach FH; Tsuji A; Sinko PJ
Biochem Biophys Res Commun; 1998 Sep; 250(2):246-51. PubMed ID: 9753615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
